
bluebird bio (BLUE) Stock Forecast & Price Target
bluebird bio (BLUE) Analyst Ratings
Bulls say
bluebird bio Inc. is emphasizing its commitment to developing potentially curative gene therapies for severe genetic diseases, including sickle cell disease and beta-thalassemia, which may lead to significant value creation and cost reduction in healthcare. The company's alignment with ESG principles suggests a strategic focus on sustainable finance, positioning bluebird bio favorably for long-term growth in the biotechnology sector. Despite currently negative gross margins, there is potential for improvement as sales increase, particularly for treatments like SCD, which have lower cost of goods sold, indicating potential future profitability.
Bears say
bluebird bio Inc. has experienced a significant revenue decline, reporting total product revenue of $16.1 million in Q2 2024, which raises concerns about the sustainability of Zynteglo's adoption nearly two years post-launch. The company faces negative gross margins and lacks clarity on how manufacturing costs might improve with future sales, indicating potential financial distress. Additionally, the persistent net losses, amounting to $61 million in the latest quarter, alongside a missed revenue consensus, suggest challenges in achieving profitable operations in the near term.
This aggregate rating is based on analysts' research of bluebird bio and is not a guaranteed prediction by Public.com or investment advice.
bluebird bio (BLUE) Analyst Forecast & Price Prediction
Start investing in bluebird bio (BLUE)
Order type
Buy in
Order amount
Est. shares
0 shares